AIM: To evaluate the effect and safety in the treatment of neovascular glaucoma(NVG)by using intravitreous injection of bevacizumab combined with Ex-press miniature glaucoma device implant with MMC.

METHODS: Nineteen eyes of 18 patients with angle-closure NVG were treated by intravitreous injection of bevacizumab combined with Ex-press miniature glaucoma device implant with MMC after atrophy of iris neovascularization. The regressions of iris neovascularization, changes of intraocular pressure, characters of filtering bleb and complications of intravitreous injection and surgery were observed in a 12 months follow-up period.

RESULTS: Iris neovascularization was completely regressed during 2-7d after injection in 16 eyes. There was no significant difference between before and after injection. The IOPs of 11 eyes were less than 21mmHg without any drugs and of 5 eyes with 1-2 kinds of anti-glaucoma drugs after combined Ex-press implant. No serious complications were observed after intravitreous injection and ex-press implant with MMC.

CONCLUSION: Intravitreous injection of bevacizumab could significantly reduce the regression of iris neovascularization, avoid haemorrhage during subsequently Ex-press implanting, relieve postoperative inflammation. It improves the successful rate of Ex-press implant with MMC and remains visual function. However, the treatment of the protopathy and potential medical treatment risk of intravitreal bevacizumab should be mentioned.